PTC Therapeutics, Inc. (NASDAQ:PTCT) CEO Stuart Walter Peltz sold 2,230 shares of the company’s stock in a transaction that occurred on Friday, January 5th. The stock was sold at an average price of $18.03, for a total transaction of $40,206.90. Following the completion of the transaction, the chief executive officer now owns 26,646 shares in the company, valued at approximately $480,427.38. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.
Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) opened at $20.93 on Friday. The stock has a market cap of $868.38, a PE ratio of -7.24 and a beta of 1.23. The company has a quick ratio of 2.97, a current ratio of 3.08 and a debt-to-equity ratio of 0.98. PTC Therapeutics, Inc. has a twelve month low of $8.12 and a twelve month high of $23.71.
PTC Therapeutics (NASDAQ:PTCT) last released its earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($0.67) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.66) by ($0.01). PTC Therapeutics had a negative return on equity of 75.19% and a negative net margin of 75.64%. research analysts expect that PTC Therapeutics, Inc. will post -2.01 earnings per share for the current fiscal year.
Several research analysts have recently weighed in on the stock. Zacks Investment Research cut shares of PTC Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, January 13th. ValuEngine raised shares of PTC Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Tuesday, January 9th. JPMorgan Chase & Co. increased their price objective on shares of PTC Therapeutics to $15.00 and gave the stock a “neutral” rating in a research note on Friday, November 24th. Bank of America cut shares of PTC Therapeutics from a “neutral” rating to an “underperform” rating in a research note on Thursday, October 26th. Finally, Cowen reissued a “hold” rating on shares of PTC Therapeutics in a research note on Wednesday, October 25th. Two analysts have rated the stock with a sell rating, seven have issued a hold rating and two have given a buy rating to the stock. PTC Therapeutics presently has an average rating of “Hold” and a consensus price target of $19.14.
A number of hedge funds have recently bought and sold shares of PTCT. Schwab Charles Investment Management Inc. increased its stake in PTC Therapeutics by 22.8% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 154,429 shares of the biopharmaceutical company’s stock worth $2,831,000 after buying an additional 28,668 shares during the period. State of Wisconsin Investment Board purchased a new position in PTC Therapeutics in the 2nd quarter worth about $440,000. Prudential Financial Inc. purchased a new position in PTC Therapeutics in the 2nd quarter worth about $201,000. Swiss National Bank increased its stake in PTC Therapeutics by 13.0% in the 2nd quarter. Swiss National Bank now owns 56,565 shares of the biopharmaceutical company’s stock worth $1,037,000 after buying an additional 6,500 shares during the period. Finally, Oppenheimer & Co. Inc. increased its stake in PTC Therapeutics by 75.1% in the 2nd quarter. Oppenheimer & Co. Inc. now owns 42,593 shares of the biopharmaceutical company’s stock worth $781,000 after buying an additional 18,273 shares during the period. 86.12% of the stock is currently owned by institutional investors.
PTC Therapeutics Company Profile
PTC Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of medicines using its expertise in ribonucleic acid (RNA) biology. Its product pipeline includes Ataluren (Translarna), PTC596 and RG7916. Its product candidate, ataluren, is an orally administered small-molecule compound for the treatment of patients with genetic disorders due to a nonsense mutation.
Receive News & Ratings for PTC Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PTC Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.